Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors.

Goebel, Lisa; Kirschner, Tonia; Koska, Sandra; Rai, Amrita; Janning, Petra; Maffini, Stefano; Vatheuer, Helge; Czodrowski, Paul; Goody, Roger S.; Müller, Müller; Rauh, Daniel

doi:10.7554/eLife.82184.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors.

MPS-Authors

/persons/resource/persons189551

Rai, Amrita
Abt. III: Strukturbiochemie, Max Planck Institute of Molecular Physiology, Max Planck Society;

/persons/resource/persons98701

Janning, Petra
Abt. IV: Chemische Biologie, Max Planck Institute of Molecular Physiology, Max Planck Society;

/persons/resource/persons118096

Maffini, Stefano
Abt. I:Mechanistische Zellbiologie, Max Planck Institute of Molecular Physiology, Max Planck Society;

/persons/resource/persons98693

Goody, Roger S.
Abt. III: Strukturbiochemie, Max Planck Institute of Molecular Physiology, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Goebel, L., Kirschner, T., Koska, S., Rai, A., Janning, P., Maffini, S., et al. (2023). Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors. eLife. doi:10.7554/eLife.82184.

Cite as: https://hdl.handle.net/21.11116/0000-000D-2FAE-C

Abstract

There is no abstract available